Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Ubunyulu > 98.0% (HPLC) Lenvatinib Mesylate Intermediate Factory
I-Ruifu Chemical Supply Lenvatinib Mesylate Intermediate with High Purity
Lenvatinib Mesylate CAS 857890-39-2
I-4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
I-Desquinolinyl Lenvatinib;I-1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
I-4-Amino-3-Chlorophenol CAS 17609-80-2
I-4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igama leMchiza | I-Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate |
Izithethantonye | Ukungcola kweLenvatinib 47;I-4-Chloro-7-Methoxyquinoline-6-Carboxylic Acid Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acid Methyl Ester;Lenvaint-D |
Inombolo yeCAS | 205448-66-4 |
Inombolo yeCAT | RF-PI1970 |
Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
Ifomula yeemolekyuli | I-C12H10ClNO3 |
Ubunzima beMolekyuli | 251.67 |
Indawo yokubilisa | 377.4±37.0℃ |
Ukuxinana | 1.320±0.06 g/cm3 |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | I-Off-White ukuya kwiPowder eqinileyo etyheli |
I-1 H NMR Spectrum | Ukungqinelana Nolwakhiwo |
Ubunyulu / Indlela yokuHlalutya | >98.0% (HPLC) |
Ilahleko ekomisweni | <1.00% |
Ukungcola ngokupheleleyo | <2.00% |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | Phakathi / Ukungacoceki kweLenvatinib Mesylate (CAS: 857890-39-2) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (i-CAS: 205448-66-4) iphakathi kweLenvatinib Mesylate (CAS: 857890-39-2).I-Lenvatinib isiyobisi somhlaza we-thyroid esakhiwe ngu-Eisai Corporation yaseJapan (iKhowudi: E7080), ehlala kwi-inhibitor ye-oral multi-receptor tyrosine kinase (RTK) kwaye inokuthintela umsebenzi we-kinase we-vascular endothelial growth factor Receptors R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4).I-Lenvatinib inokuthintela ukubandakanyeka kwezinye ii-RTKs kwi-angiogenesis ye-pathological, ukukhula kwe-tumor, kunye nokuqhubela phambili komhlaza ngaphandle kwemisebenzi yabo eqhelekileyo yeselula kubandakanya i-fibroblast growth factor (FGF) receptors FGFR1, 2, 3, kunye ne-4;I-Platelet-derived growth factor receptor (PDGFR [alpha]), i-KIT, kunye ne-RET.[Izibonakaliso]: I-Lenvatinib ifanelekile kunyango lwezigulane zomhlaza we-thyroid wokuphindaphinda kwendawo okanye uhlobo lwe-metastasis, uhlobo lwe-progressivity kunye ne-radioactive iodine-refractory differentiated type.